SYNOPSIS Cross-reacting factor IX material (CRM) was immunologically detected in the plasma of 38 normal individuals and 21 out of 22 haemophilia B patients using a rabbit antibody to factor IX. The same reacting material was detected in only nine of these patients using a human antibody. These results indicate that the plasma of the majority of haemophilia B patients contains a protein-lacking biological activity but having antigenic determinants in common with normal factor IX.
Genetic variants of haemophilia A and B (factor VIII and IX deficiencies) have been recently demonstrated by the ability or inability of the patient's plasma to neutralize specific human antibodies against factor VIII or IX (Roberts, Gross, Webster, and Dejanov, 1966; Denson, Biggs, and Mannucci, 1968; Hoyer and Breckenridge, 1968; Roberts, Grizzle, McLester, and Penick, 1968; Feinstein, Chong, Kasper, and Rapaport, 1969; Denson, Biggs, Haddon, Borrett, and Cobb, 1969; Brown, Hougie, and Roberts, 1970; Meyer, Dray, and Larrieu, 1970; Hoyer and Breckenridge, 1970; Meyer and Larrieu, 1971) . In most patients (haemophilia A-or B-) immunological cross-reacting material was absent, while in 10 to 15% of them an inactive protein could be demonstrated (haemophilia A+ or B+). However, conflicting data were obtained in haemophilia A when using factor VIII antibodies raised in different species (rabbit, goat) by immunization with partially purified factor VIII. Depending on the reactivity of the various antibodies, inactive cross-reacting material could be demonstrated in a highly variable percentage of haemophilia A patients: 100 % (Zimmerman, Ratnoff, and Powell, 1971; Stites, Hershgold, Perlman, and Fudenberg, 1971; Meyer, Lavergne, Larrieu, and Josso, 1972) , 90% (Bennett and Huehns, 1970) , or around 15% (Denson et al, 1969; Gralnick, Abrell, and Bagley, 1971 ). The present study demonstrates a similar discrepancy when the reactivity of different haemophilia B plasmas was compared with two types of factor IX antibodies, namely, a human inhibitor which occurred in a transfused haemophilia B patient, and rabbit antibodies raised by immunization with a partially purified antigen.
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Materials and Methods
The factor IX concentrate used as a source of antigen was a sample from a batch of human material (RD40) prepared at the Oxford Haemophilia Centre by batch adsorption on DEAE-ellulose followed by displacement elution in a column (Dike, Bidwell, and Rizza, 1972) . This concentrate contained 62 U/ml factor IX, 50 U/ml factor 11, 44 U/ml factor X, and a very low concentration of factor VII (1-7 U/ml). The protein concentration was 10 mg/ml and the purification with respect to factor IX was 400-fold.
Rabbit antisera were obtained by injection of equal parts of factor IX concentrate and complete Freund's adjuvant. Three injections (6 mg protein) were given at intervals of eight days, the first one in the popliteal lymph node and subsequent ones in foot pads. Blood was drawn 10 days after the last injection, and allowed to clot in glass tubes, which were kept at 370 C for six hours and at 4°C for-12 hours. Serum was obtained by centrifugation at 5000 g for 15 min, oxalated, adsorbed with barium carbonate (40 mg/ml), and heated at 56°C for 30 minutes. The antibody titres (Denson, 1967) were 5 U/ml and 18 U/ml (1 U was defined as the amount of serum destroying 75 % factor IX after incubation at 37°C for 15 min). The anti-factor II and antifactor X antibody titres were < 2 U/ml. These antibodies were not specific for factor IX, as by immunodiffusion four lines of precipitation were shown against normal plasma or factor IX concentrate.
Human factor IX antibody was a specific inhibitor which appeared in a haemophilia B patient after multiple transfusions. The antibody titre was 15 U/ml. 433 Factor IX activity was measured by a one-stage assay (Langdell, Wagner, and Brinkhous, 1953) , and prothrombin time with human and ox-brain thromboplastin (Thrombotest) as previously described (Meyer and Larrieu, 1971) .
Inhibitor-neutralizing activity was measured by a modified two-stage procedure (Denson et al, 1969) . In the first step, 04 ml of normal or test plasma was incubated at 37°C for 15 min with 0-1 ml of an appropriate dilution of human or rabbit antibody. In the second step, 0-2 ml of normal plasma was added to an equal volume of the first mixture. After a second incubation at 37°C for 15 min residual factor IX was measured by a one-stage assay. Results were expressed as units of neutralized inhibitor.
Results

INHIBITOR-NEUTRALIZING ACTIVITY IN CON-TROL PLASMAS
The specificity of the factor IX assays ensures the specificity of the inhibitor-neutralizing technique for the antigenic determinants of factor IX. Other coagulation factor antibodies, such as anti-factor VII (from human or rabbit origin) or rabbit antihuman factor I,1 tested in the same system, did not interfere with the final assay of factor IX after the two incubations.
Inhibitor-neutralizing activity was measured in normal plasma (38 experiments): it varied from 0-85 to 1-07 unit (mean 1-03 ± 0-07 unit) when using (Fig. 1) , and from 0-85 to 1-25 unit (mean 0-92 ± 0.05 unit) when using antihuman factor IX antiserum (Fig. 2) . Cross-reacting material was present in normal serum as well as in the plasma of coagulation deficiencies other than factor IX. It was lacking in aluminium hydroxide or barium sulphate-adsorbed plasma or serum, the results being the same as those with citrated saline.
INHIBITOR-NEUTRALIZING ACTIVITY IN PATIENTS WITH HAEMOPHILIA B
Twenty-two haemophilia B patients were tested in the same way using both human and rabbit antibodies.
Human antibody Plasma samples from 13 haemophilia B patients failed to neutralize the human antibody. These patients were classified as haemophilia B-. Five plasmas contained an amount of cross-reacting material identical to that in normal plasma, and four showed intermediate results (Fig. 1) . These nine patients were classified as haemophilia B+.
Rabbit antiserum
The capacity of the same plasmas to neutralize the rabbit antihuman factor IX antibodies appeared entirely different. Only one patient out of the 22 tested lacked immunologically detectable crossreacting material (Fig. 2) . This patient had a moderate form of haemophilia B (factor IX activity 4%). In 14 patients plasma inhibitor neutralizing activity varied from 0-65 to 1 1 unit, ie, within the normal * (Hougie and Twomey, 1967) . Cross-reacting material was present in three of these patients when tested by human antibody, and in all five when tested with rabbit antibody (Table I) . Among the 22 patients with haemophilia B we studied with both methods, four groups could be distinguished when using factor IX human antibody (Table II) . In the first group (11 patients with a severe or a moderate form of the disease), the Thrombotest was normal and antigenic activity lacking. In the second group (six patients with moderate haemophilia), the Thrombotest was normal, and the plasma (Table II) . Twenty-one patients were classified in groups II and IV (haemophilia B+), and one in group I.
Discussion
A large heterogeneity with a wide spectrum of variants had already been demonstrated in haemophilia B when using a human factor IX inhibitor.
Two different molecular abnormalities have been recently described: haemophilia BM (Hougie and Twomey, 1967) and haemophilia B+ (Denson et al, 1968; Roberts et al, 1968; Meyer and Larrieu, 1971 
